Cesca Therapeutics Announces Senior Management Promotions
April 03 2017 - 6:00AM
Cesca Therapeutics Inc. (Nasdaq:KOOL), a market leader in automated
cell processing and point-of-care, autologous cell-based therapies,
today announced the following senior management promotions,
effective immediately.
- Ms. Haihong Zhu, who most recently served as Director of Sales,
has been promoted to the newly-created position of General Manager
of ThermoGenesis, Cesca’s device division. Ms. Zhu has been
with Cesca since 2004, serving in various technical and sales
positions, and contributed significantly to the establishment of
Cesca’s commercial presence in China.
- Dr. Dalip Sethi, who has served as Director of Clinical
Research (USA), has been promoted to the position of Senior
Director of Research and Development. Dr. Sethi, who has been
with the Company since 2012, will spearhead Cesca’s clinical
development of novel cell therapy methods for treating vascular and
orthopedic diseases.
- Mr. Jeff Cauble, most recently holding the position of Director
of Finance, has been promoted to the position of Principal
Accounting Officer. Mr. Cauble has been with Cesca since
2010 and has served in various accounting management positions of
increasing responsibility.
“These senior team members have contributed
greatly to our success in developing and commercializing our
proprietary cell-based therapies and devices, and I am delighted to
recognize their ongoing leadership and commitment to the company
through these promotions,” said Chris Xu, interim Chief Executive
Officer of Cesca. “We are fortunate at Cesca to have a deep and
seasoned management team, and with these key individuals assuming
expanded roles, we believe we have the team in place to
successfully shepherd Cesca Therapeutics through its next phase of
growth.”
About Cesca Therapeutics
Inc.
About Cesca (www.cescatherapeutics.com):
Cesca is engaged in the research, development, and
commercialization of cellular therapies and delivery systems for
use in regenerative medicine. The Company is a leader in the
development and manufacture of automated blood and bone marrow
processing systems that enable the separation, processing and
preservation of cell and tissue therapeutics.
Forward-Looking StatementThe
statements contained herein may include statements of future
expectations and other forward-looking statements that are based on
management’s current views and assumptions and involve known and
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. A more complete description of risks
that could cause actual events to differ from the outcomes
predicted by Cesca Therapeutics' forward-looking statements is set
forth under the caption "Risk Factors" in Cesca Therapeutics annual
report on Form 10-K and other reports it files with the Securities
and Exchange Commission from time to time, and you should consider
each of those factors when evaluating the forward-looking
statements.
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Apr 2023 to Apr 2024